New Implant Technology Offers Hope for Managing Obesity and Diabetes in Cats
Vivani Medical (VANI) has announced a significant breakthrough in treating feline obesity and diabetes with its innovative OKV-119 implant. Detailed in the peer-reviewed BMC Veterinary Research, the study demonstrates that a single OKV-119 implant can effectively deliver exenatide, a weight-loss drug, over a three-month period.
OKV-119, developed in partnership with Okava Pharmaceuticals, is a miniature, subdermal implant designed for insertion during routine veterinary visits. The implant ensures a steady release of exenatide, maintaining plasma concentrations between 1.5 ng/ml and 4 ng/ml, which successfully induced weight loss in cats.
This development is particularly noteworthy given that up to 40% of domestic cats suffer from obesity, a condition linked to decreased life expectancy and various health issues. The success of OKV-119 in managing feline weight opens new avenues for addressing one of the most common health challenges in veterinary medicine.
Adam Mendelsohn, President and CEO of Vivani, highlighted the broader implications of this technology, noting that the similarities in obesity phenotypes between humans and felines support the potential for using NanoPortal implant technology in chronic weight management for both cats and humans.
Vivani plans to extend the implant’s duration to six months, building on prior demonstrations of exenatide delivery in vitro and in vivo. This advancement underscores the potential of OKV-119 to revolutionize the treatment of obesity and diabetes in companion animals and possibly humans.
You might like this article:GameStop Surges 20% After-Hours Following Successful $1B Share Sale
